About Clearmind Medicine Inc.
https://www.clearmindmedicine.comClearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors.
CEO
Adi Zuloff-Shani
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-15 | Reverse | 1:40 |
| 2023-11-28 | Reverse | 1:30 |
Ratings Snapshot
Rating : C+
Price Target
About Clearmind Medicine Inc.
https://www.clearmindmedicine.comClearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.4M ▲ | $-1.31M ▼ | 0% | $-0.34 ▼ | $-1.28M ▲ |
| Q2-2025 | $0 | $1.31M ▼ | $-783.93K ▲ | 0% | $-0.21 ▲ | $-1.3M ▼ |
| Q1-2025 | $0 | $1.48M ▼ | $-1.07M ▼ | 0% | $-0.35 ▼ | $-1.01M ▲ |
| Q4-2024 | $0 | $1.57M ▲ | $-884.74K ▲ | 0% | $-0.3 ▲ | $-1.18M ▲ |
| Q3-2024 | $0 | $1.46M | $-2.09M | 0% | $-0.81 | $-1.46M |
What's going well?
The company is investing heavily in research and development, which could pay off if it leads to a future product. Other income helped soften the loss a bit this quarter.
What's concerning?
There is still no revenue, costs are rising, and losses are getting worse. The company is also diluting shareholders by issuing more shares.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.5M ▼ | $3.97M ▼ | $2.9M ▲ | $1.07M ▼ |
| Q2-2025 | $4.65M ▼ | $5.18M ▼ | $2.88M ▼ | $2.3M ▼ |
| Q1-2025 | $5.92M ▼ | $6.58M ▼ | $3.73M ▼ | $2.85M ▼ |
| Q4-2024 | $6.86M ▼ | $7.26M ▼ | $4.15M ▼ | $3.11M ▼ |
| Q3-2024 | $7.68M | $8.17M | $4.7M | $3.47M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.31M ▼ | $-1.08M ▲ | $112.95K ▲ | $-10.81K ▼ | $-977.18K ▲ | $-1.5M ▼ |
| Q2-2025 | $-783.93K ▲ | $-1.1M ▲ | $-200K ▼ | $-10.3K ▼ | $-1.31M ▼ | $-1.1M ▲ |
| Q1-2025 | $-1.07M ▼ | $-1.27M ▼ | $69.46K ▲ | $404.81K ▲ | $-792.62K ▲ | $-1.27M ▼ |
| Q4-2024 | $-884.74K ▲ | $-1.08M ▲ | $-350.4K ▼ | $323.2K ▼ | $-1.11M ▼ | $-1.09M ▲ |
| Q3-2024 | $-2.09M | $-1.13M | $33.8K | $469.54K | $-626.28K | $-1.13M |
CEO
Adi Zuloff-Shani
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-15 | Reverse | 1:40 |
| 2023-11-28 | Reverse | 1:30 |
Ratings Snapshot
Rating : C+